| Date | Title | | | 09/06/16 | Forward Pharma CFO to Participate in Three Investor Conferences in September| COPENHAGEN, Denmark, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, the Company’s Chief Financial Officer, will participate in the following conferences:
Wells Fargo Securities Healthcare Conference to be held at the Westin Boston Waterfront in Boston, Mas... |
|  | | 09/01/16 | Forward Pharma Reports Second Quarter 2016 Financial and Operational Results| COPENHAGEN, Denmark, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the second quarter ended June 30, 2016. Net loss for the second quarter ended June 30, 2016 was $15.1 million, or $0.32 per basic share versus a net loss of $17.7 million, or $0.38 per basic share for second quarter of 2015. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our second quarter net ... |
| | | 06/06/16 | Forward Pharma CFO to Participate in Two Investor Conferences in June| COPENHAGEN, Denmark, June 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, the Company’s Chief Financial Officer, will participate in the following conferences:
Jefferies Healthcare Conference to be held at the Grand Hyatt in New York, New York. Mr. Sendek will p... |
| | | 06/02/16 | Forward Pharma Reports First Quarter 2016 Financial and Operational Results| COPENHAGEN, Denmark, June 02, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the first quarter ended March 31, 2016. Net loss for the first quarter ended March 31, 2016 was $16.9 million, or $(0.36) per basic share versus net income of $6.0 million, or $0.13 per basic share for first quarter of 2015. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our first quarter net lo... |
| |
|
